{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:44:09Z","timestamp":1793234649992,"version":"4.5.0"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Efficacy of the Janus kinase (JAK) inhibitor baricitinib for severe alopecia areata (AA) continuously increased over 52\u2009weeks in two Phase 3 trials. There are limited long\u2010term data on JAK inhibitors in AA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate efficacy and safety of baricitinib for severe AA through 104\u2009weeks of continuous therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Integrated data from the BRAVE\u2010AA1 and BRAVE\u2010AA2 Phase 3 trials included adults with Severity of Alopecia Tool (SALT) scores \u226550 (\u226550% scalp hair loss) randomized to and continuously treated with 2\u2010mg or 4\u2010mg baricitinib through Week 104. Patients who qualified to remain on continuous treatment included subjects who achieved SALT score \u226420 at Week 52 (Week\u201052 responders; 2\u2010mg:\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200965; 4\u2010mg:\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009129) and baricitinib 4\u2010mg\u2010treated patients who had SALT score &gt;20 at Week 52 but achieved SALT score \u226420 at prior visit(s) and\/or had significant improvement in eyebrow or eyelash hair growth relative to baseline by Week 52 (Week\u201052 mixed responders;\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009110). Week\u2010104 outcomes included the proportion of patients achieving SALT score \u226420 (\u226420% scalp hair loss). Data were censored after treatment discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among baricitinib 4\u2010mg\u2010treated and baricitinib 2\u2010mg\u2010treated Week\u201052 responders, 90.7% and 89.2%, respectively, maintained SALT score \u226420 at Week 104. Among Week\u201052 mixed responders, 39.1% reached SALT score \u226420 by Week 104. Continued improvement in eyebrow and eyelash regrowth was observed across groups. The most frequent treatment\u2010emergent adverse events were COVID\u201019, upper respiratory tract infection, headache, nasopharyngitis, acne, urinary tract infection and creatine phosphokinase increase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baricitinib demonstrated a high level of maintenance of efficacy over 104\u2009weeks in patients with severe AA. Efficacy increased in Week\u201052 mixed responders, illustrating that long\u2010term treatment is necessary to observe maximum benefit in some patients. No new safety signals were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.19665","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T08:57:16Z","timestamp":1708678636000},"page":"583-593","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["<scp>Long\u2010term<\/scp>\n                    efficacy and safety of baricitinib in patients with severe\u00a0alopecia areata:\n                    <scp>104\u2010week<\/scp>\n                    results from\n                    <scp>BRAVE\u2010AA1<\/scp>\n                    and\n                    <scp>BRAVE\u2010AA2<\/scp>"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-520X","authenticated-orcid":false,"given":"M.","family":"Senna","sequence":"first","affiliation":[{"name":"Lahey Hospital and Medical Center, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5617","authenticated-orcid":false,"given":"A.","family":"Mostaghimi","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ohyama","sequence":"additional","affiliation":[{"name":"Kyorin University Faculty of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Dutronc","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. S.","family":"Wu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Yu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chiasserini","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Somani","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Holzwarth","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-4616","authenticated-orcid":false,"given":"B.","family":"King","sequence":"additional","affiliation":[{"name":"Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00240-7"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.035"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15994"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.008"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15489"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.05.027"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00764-w"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00545-9"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.09.032"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18883"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19024"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-29"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/120347540100500202"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac059"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02281-4"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T06:36:33Z","timestamp":1708929393000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/jdv.19665"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19665","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"2023-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}